Literature DB >> 1969559

Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide.

M E McManaway1, L M Neckers, S L Loke, A A al-Nasser, R L Redner, B T Shiramizu, W L Goldschmidts, B E Huber, K Bhatia, I T Magrath.   

Abstract

In a high proportion of Burkitt lymphomas, transcription of the c-myc gene is initiated from a cryptic promoter in the first intron, creating abnormal messenger RNA molecules in which intron sequences, normally spliced out of the nascent transcripts, persist. An antisense oligodeoxynucleotide directed against these intron sequences greatly inhibited the proliferation of Burkitt lymphoma cell lines containing the abnormal transcripts (ST486 and JD38), but not that of cell lines containing normal c-myc transcripts (KK124). Flow cytometry showed a pronounced reduction in intracellular c-myc protein levels in cell lines containing aberrant myc transcripts, but no change in other cellular proteins. Control oligonucleotide did not inhibit c-myc protein expression or growth. These experiments provide evidence that antisense oligonucleotides targeted against tumour-specific, aberrant RNA species could be effective in controlling the proliferation of tumour cells without affecting normal cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969559     DOI: 10.1016/0140-6736(90)90934-w

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  Molecular biology in medicine.

Authors:  B D Young
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

2.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

3.  Intracellular distribution of microinjected antisense oligonucleotides.

Authors:  J P Leonetti; N Mechti; G Degols; C Gagnor; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

Review 4.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

Review 5.  Pathogenesis of AIDS-related lymphomas: molecular and histogenetic heterogeneity.

Authors:  G Gaidano; A Carbone; R Dalla-Favera
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

6.  Gene therapy in gastroenterology.

Authors:  H S Pandha; N R Lemoine
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

7.  The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides.

Authors:  S Morelli; D Delia; S Capaccioli; A Quattrone; N Schiavone; A Bevilacqua; S Tomasini; A Nicolin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

8.  Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides.

Authors:  I Demirhan; O Hasselmayer; D Hofmann; A Chandra; F P Svinarchuk; V V Vlassov; J Engels; P Chandra
Journal:  Virus Genes       Date:  1995-01       Impact factor: 2.332

Review 9.  Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity.

Authors:  G Gaidano; C Pastore; C Lanza; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

10.  Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate.

Authors:  Y Huang; R Snyder; M Kligshteyn; E Wickstrom
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.